|
1
|
World Health Organization: HIV/AIDS fact
sheet. 2018 12–February. 2018http://www.who.int/en/news-room/fact-sheets/detail/hiv-aids
|
|
2
|
McMahon JH, Elliott JH, Bertagnolio S,
Kubiak R and Jordan MR: Viral suppression after 12 months of
antiretroviral therapy in low- and middle-income countries: A
systematic review. Bull World Health Organ. 91:377–385. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thompson MA, Aberg JA, Hoy JF, Telenti A,
Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, et al:
Antiretroviral treatment of adult HIV infection: 2012
recommendations of the International Antiviral Society-USA panel.
JAMA. 308:387–402. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Castronuovo D, Cacopardo B, Pinzone MR, Di
Rosa M, Martellotta F, Schioppa O, Moreno S and Nunnari G: Bone
disease in the setting of HIV infection: Update and review of the
literature. Eur Rev Med Pharmacol Sci. 17:2413–2419.
2013.PubMed/NCBI
|
|
5
|
Scarpino M, Pinzone MR, Di Rosa M, Madeddu
G, Focà E, Martellotta F, Schioppa O, Ceccarelli G, Celesia BM,
d'Ettorre G, et al: Kidney disease in HIV-infected patients. Eur
Rev Med Pharmacol Sci. 17:2660–2667. 2013.PubMed/NCBI
|
|
6
|
Pomerantz RJ and Nunnari G: HIV and GB
virus C-can two viruses be better than one? N Engl J Med.
350:963–965. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nunnari G, Coco C, Pinzone MR, Pavone P,
Beretta M, Di Rosa M, Schnell M, Giorgio C and Cacopando B: The
role of micronutrients in the diet of HIV-1-infected individuals.
Front Biosci (Elite Ed). 4:2442–2456. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pinzone MR, Berretta M, Cacopardo B and
Nunnari G: Epstein-barr virus- and Kaposi sarcoma-associated
herpesvirus-related malignancies in the setting of human
immunodeficiency virus infection. Semin Oncol. 42:258–271. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pinzone MR, Di Rosa M, Celesia BM,
Condorelli F, Malaguarnera M, Madeddu G, Martellotta F, Castronuovo
D, Gussio M, Coco C, et al: LPS and HIV gp120 modulate
monocyte/macrophage CYP27B1 and CYP24A1
expression leading to vitamin D consumption and hypovitaminosis D
in HIV-infected individuals. Eur Rev Med Pharmacol Sci.
17:1938–1950. 2013.PubMed/NCBI
|
|
10
|
Pinzone MR, Cacopardo B, Condorelli F, Di
Rosa M and Nunnari G: Sirtuin-1 and HIV-1: An overview. Curr Drug
Targets. 14:648–652. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Capetti A, Landonio S, Meraviglia P, Di
Biagio A, Lo Caputo S, Sterrantino G, Ammassari A, Menzaghi B,
Franzetti M, De Socio GV, et al: 96 Week follow-up of HIV-infected
patients in rescue with raltegravir plus optimized backbone
regimens: A multicentre Italian experience. PLoS One. 7:e392222012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Visalli G, Paiardini M, Chirico C, Cervasi
B, Currò M, Ferlazzo N, Bertuccio MP, Favaloro A, Pellicanò G,
Sturniolo G, et al: Intracellular accumulation of cell cycle
regulatory proteins and nucleolin re-localization are associated
with pre-lethal ultrastructural lesions in circulating T
lymphocytes: The HIV-induced cell cycle dysregulation revisited.
Cell Cycle. 9:2130–2140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Celesia BM, Nigro L, Pinzone MR, Coco C,
La Rosa R, Bisicchia F, Mavilla S, Gussio M, Pellicanò G, Milioni
V, et al: High prevalence of undiagnosed anxiety symptoms among
HIV-positive individuals on cART: A cross-sectional study. Eur Rev
Med Pharmacol Sci. 17:2040–2046. 2013.PubMed/NCBI
|
|
14
|
Visalli G, Bertuccio MP, Currò M,
Pellicanò G, Sturniolo G, Carnevali A, Spataro P, Ientile R,
Picerno I, Cavallari V, et al: Bioenergetics of T cell activation
and death in HIV type 1 infection. AIDS Res Hum Retroviruses.
28:1110–1118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Trovato M, Ruggeri RM, Sciacchitano S,
Vicchio TM, Picerno I, Pellicanò G, Valenti A and Visalli G: Serum
interleukin-6 levels are increased in HIV-infected patients that
develop autoimmune disease during long-term follow-up.
Immunobiology. 223:264–268. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
D'Aleo F, Ceccarelli M, Venanzi Rullo E,
Facciolà A, Di Rosa M, Pinzone MR, Condorelli F, Visalli G, Picerno
I, Berretta M, et al: Hepatitis C-related hepatocellular carcinoma:
Diagnostic and therapeutic management in HIV-patients. Eur Rev Med
Pharmacol Sci. 21:5859–5867. 2017.PubMed/NCBI
|
|
17
|
Squillace N, Ricci E, Quirino T, Gori A,
Bandera A, Carenzi L, De Socio GV, Orofino G, Martinelli C, Madeddu
G, et al CISAI Study Group, : Safety and tolerability of
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate
in a real life setting: Data from surveillance cohort long-term
toxicity antiretrovirals/antivirals (SCOLTA) project. PLoS One.
12:e01792542017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Facciolà A, Venanzi Rullo E, Ceccarelli M,
D'Aleo F, Di Rosa M, Pinzone MR, Condorelli F, Visalli G, Picerno
I, Fisichella R, et al: Kaposi's sarcoma in HIV-infected patients
in the era of new antiretrovirals. Eur Rev Med Pharmacol Sci.
21:5868–5869. 2017.PubMed/NCBI
|
|
19
|
Zanet E, Berretta M, Benedetto FD,
Talamini R, Ballarin R, Nunnari G, Berretta S, Ridolfo A, Lleshi A,
Zanghì A, et al: Pancreatic cancer in HIV-positive patients: A
clinical case-control study. Pancreas. 41:1331–1335. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nunnari G, Sullivan J, Xu Y, Nyirjesy P,
Kulkosky J, Cavert W, Frank I and Pomerantz RJ: HIV type 1
cervicovaginal reservoirs in the era of HAART. AIDS Res Hum
Retroviruses. 21:714–718. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nunnari G, Leto D, Sullivan J, Xu Y,
Mehlman KE, Kulkosky J and Pomerantz RJ: Seminal reservoirs during
an HIV type 1 eradication trial. AIDS Res Hum Retroviruses.
21:768–775. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Martellotta F, Berretta M, Cacopardo B,
Fisichella R, Schioppa O, Zanghì A, Spartà D, Cappellani A,
Talamini R, Izzi I, et al: Clinical presentation and outcome of
squamous cell carcinoma of the anus in HIV-infected patients in the
HAART-era: A GICAT experience. Eur Rev Med Pharmacol Sci.
16:1283–1291. 2012.PubMed/NCBI
|
|
23
|
Celesia BM, Castronuovo D, Pinzone MR,
Bellissimo F, Mughini MT, Lupo G, Scarpino MR, Gussio M, Palermo F,
Cosentino S, et al: Late presentation of HIV infection: Predictors
of delayed diagnosis and survival in Eastern Sicily. Eur Rev Med
Pharmacol Sci. 17:2218–2224. 2013.PubMed/NCBI
|
|
24
|
Bearz A, Vaccher E, Martellotta F, Spina
M, Talamini R, Lleshi A, Cacopardo B, Nunnari G, Berretta M,
Tirelli U, et al: Lung cancer in HIV positive patients: Τhe GICAT
experience. Eur Rev Med Pharmacol Sci. 18:500–508. 2014.PubMed/NCBI
|
|
25
|
Capetti A, Meraviglia P, Landonio S,
Sterrantino G, Di Biagio A, Lo Caputo S, Ammassari A, Menzaghi B,
De Socio GV, Franzetti M, et al: Four years data of
raltegravir-based salvage therapy in HIV-1-infected,
treatment-experienced patients: The SALIR-E study. Int J Antimicrob
Agents. 43:189–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nuvoli S, Caruana G, Babudieri S, Solinas
P, Pellicanò G, Piras B, Fiore V, Bagella P, Calia GM, Yue M, et
al: Body fat changes in HIV patients on highly active
antiretroviral therapy (HAART): A longitudinal DEXA study. Eur Rev
Med Pharmacol Sci. 22:1852–1859. 2018.PubMed/NCBI
|
|
27
|
Ceccarelli M, Condorelli F, Venanzi Rullo
E and Pellicanò GF: Editorial - Improving access and adherence to
screening tests for cancers: A new, though old, challenge in the
HIV epidemics. World Cancer Res J. 5:e10302018.
|
|
28
|
Ceccarelli M, Rullo EV, Facciolà A,
Madeddu G, Cacopardo B, Taibi R, D'Aleo F, Pinzone MR, Picerno I,
di Rosa M, et al: Head and neck squamous cell carcinoma and its
correlation with human papillomavirus in people living with HIV: A
systematic review. Oncotarget. 9:17171–17180. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
D'Aleo F, Cama BAV, Paolucci IA, et al:
New and old assumptions on lung cancer in People Living with HIV.
World Cancer Res J. 5:e10362018.
|
|
30
|
Visalli G, Facciolà A, D'Aleo F, Pinzone
MR, Condorelli F, Nunnari G, Pellicano GF, Ceccarelli M and Venanzi
Rullo E: HPV and urinary bladder carcinoma: A review of the
literature. World Cancer Res J. 5:e10382018.
|
|
31
|
Pace MJ, Agosto L, Graf EH and O'Doherty
U: HIV reservoirs and latency models. Virology. 411:344–354. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wyatt R and Sodroski J: The HIV-1 envelope
glycoproteins: Fusogens, antigens, and immunogens. Science.
280:1884–1888. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Briz V, Poveda E and Soriano V: HIV entry
inhibitors: Mechanisms of action and resistance pathways. J
Antimicrob Chemother. 57:619–627. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ray S, Fatima Z and Saxena A: Drugs for
AIDS. Mini Rev Med Chem. 10:147–161. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jacobson JM, Saag MS, Thompson MA, Fischl
MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman
BS, Patel MC, et al: Antiviral activity of single-dose PRO 140, a
CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis.
198:1345–1352. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Trkola A, Ketas TJ, Nagashima KA, Zhao L,
Cilliers T, Morris L, Moore JP, Maddon PJ and Olson WC: Potent,
broad-spectrum inhibition of human immunodeficiency virus type 1 by
the CCR5 monoclonal antibody PRO 140. J Virol. 75:579–588. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jacobson JM, Thompson MA, Lalezari JP,
Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y,
Marozsan AJ, Maddon PJ, et al: Anti-HIV-1 activity of weekly or
biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal
antibody. J Infect Dis. 201:1481–1487. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
CytoDyn Inc: An extension of protocol PRO
140_CD01 TS Study. ClinicalTrials.gov. Identifier: NCT02355184.
First posted. February 4–2015, https://clinicaltrials.gov/ct2/show/NCT02355184
|
|
39
|
CytoDyn Inc: A randomized, double-blind,
placebo-controlled trial, followed by single-arm treatment of PRO
140 in combination w/optimized background therapy in
treatment-experienced HIV subjects (PRO 140). ClinicalTrials.gov.
Identifier: NCT02483078. First posted. June 26–2015, https://clinicaltrials.gov/ct2/show/NCT02483078
|
|
40
|
Baba M, Takashima K, Miyake H, Kanzaki N,
Teshima K, Wang X, Shiraishi M and Iizawa Y: TAK-652 inhibits
CCR5-mediated human immunodeficiency virus type 1 infection in
vitro and has favorable pharmacokinetics in humans. Antimicrob
Agents Chemother. 49:4584–4591. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Marier J-F, Trinh M, Pheng LH, Palleja SM
and Martin DE: Pharmacokinetics and pharmacodynamics of TBR-652, a
novel CCR5 antagonist, in HIV-1-infected, antiretroviral
treatment-experienced, CCR5 antagonist-naïve patients. Antimicrob
Agents Chemother. 55:2768–2774. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Thompson M, Saag M, DeJesus E, Gathe J,
Lalezari J, Landay AL, Cade J, Enejosa J, Lefebvre E and Feinberg
J: A 48-week randomized phase 2b study evaluating cenicriviroc
versus efavirenz in treatment-naive HIV-infected adults with C-C
chemokine receptor type 5-tropic virus. AIDS. 30:869–878. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lalezari J, Gathe J, Brinson C, Thompson
M, Cohen C, Dejesus E, Galindez J, Ernst JA, Martin DE and Palleja
SM: Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2
antagonist, in HIV-1-infected, treatment-experienced, CCR5
antagonist-naive subjects. J Acquir Immune Defic Syndr. 57:118–125.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Baba M, Miyake H, Wang X, Okamoto M and
Takashima K: Isolation and characterization of human
immunodeficiency virus type 1 resistant to the small-molecule CCR5
antagonist TAK-652. Antimicrob Agents Chemother. 51:707–715. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Visseaux B, Charpentier C, Collin G,
Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E,
Brun-Vézinet F and Descamps D; ANRS CO5 HIV-2 Cohort, :
Cenicriviroc, a novel CCR5 (R5) and CCR2 antagonist, shows in vitro
activity against R5 Tropic HIV-2 Clinical Isolates. PLoS One.
10:e01349042015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Polianova MT, Ruscetti FW, Pert CB and
Ruff MR: Chemokine receptor-5 (CCR5) is a receptor for the HIV
entry inhibitor peptide T (DAPTA). Antiviral Res. 67:83–92. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pollicita M, Ruff MR, Pert CB, Polianova
MT, Schols D, Ranazzi A, Perno CF and Aquaro S: Profound anti-HIV-1
activity of DAPTA in monocytes/macrophages and inhibition of
CCR5-mediated apoptosis in neuronal cells. Antivir Chem Chemother.
18:285–295. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Goodkin K, Vitiello B, Lyman WD, Asthana
D, Atkinson JH, Heseltine PN, Molina R, Zheng W, Khamis I, Wilkie
FL, et al: Cerebrospinal and peripheral human immunodeficiency
virus type 1 load in a multisite, randomized, double-blind,
placebo-controlled trial of D-Ala1-peptide T-amide for
HIV-1-associated cognitive-motor impairment. J Neurovirol.
12:178–189. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Agrawal L, Ducoudret O, Baichoo N,
Laznicka M, Ruff M and Pert C: mDAPTA, a potent CCR5 receptor
blocker, prevents viral recovery from CD8-depleted patient PBMCs
with VL< 50 background. International AIDS Society. http://www.abstract-archive.org/Abstract/Share/4495
|
|
50
|
Polianova MT, Ruscetti FW, Pert CB,
Tractenberg RE, Leoung G, Strang S and Ruff MR: Antiviral and
immunological benefits in HIV patients receiving intranasal peptide
T (DAPTA). Peptides. 24:1093–1098. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Langley DR, Kimura SR, Sivaprakasam P,
Zhou N, Dicker I, McAuliffe B, Wang T, Kadow JF, Meanwell NA and
Krystal M: Homology models of the HIV-1 attachment inhibitor
BMS-626529 bound to gp120 suggest a unique mechanism of action.
Proteins. 83:331–350. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Nowicka-Sans B, Gong Y-F, McAuliffe B,
Dicker I, Ho HT, Zhou N, Eggers B, Lin PF, Ray N, Wind-Rotolo M, et
al: In vitro antiviral characteristics of HIV-1 attachment
inhibitor BMS-626529, the active component of the prodrug
BMS-663068. Antimicrob Agents Chemother. 56:3498–3507. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li Z, Zhou N, Sun Y, Ray N, Lataillade M,
Hanna GJ and Krystal M: Activity of the HIV-1 attachment inhibitor
BMS-626529, the active component of the prodrug BMS-663068, against
CD4-independent viruses and HIV-1 envelopes resistant to other
entry inhibitors. Antimicrob Agents Chemother. 57:4172–4180. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ray N, Hwang C, Healy MD, Whitcomb J,
Lataillade M, Wind-Rotolo M, Krystal M and Hanna GJ: Prediction of
virological response and assessment of resistance emergence to the
HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with
its prodrug BMS-663068. J Acquir Immune Defic Syndr. 64:7–15. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhou N, Nowicka-Sans B, McAuliffe B, Ray
N, Eggers B, Fang H, Fan L, Healy M, Langley DR, Hwang C, et al:
Genotypic correlates of susceptibility to HIV-1 attachment
inhibitor BMS-626529, the active agent of the prodrug BMS-663068. J
Antimicrob Chemother. 69:573–581. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Nettles RE, Schürmann D, Zhu L, Stonier M,
Huang SP, Chang I, Chien C, Krystal M, Wind-Rotolo M, Ray N, et al:
Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an
oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J
Infect Dis. 206:1002–1011. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lalezari JP, Latiff GH, Brinson C,
Echevarría J, Treviño-Pérez S, Bogner JR, Thompson M, Fourie J,
Sussmann Pena OA, Mendo Urbina FC, et al: Safety and efficacy of
the HIV-1 attachment inhibitor prodrug BMS-663068 in
treatment-experienced individuals: 24 week results of AI438011, a
phase 2b, randomised controlled trial. Lancet HIV. 427–37. 2015.
View Article : Google Scholar
|
|
58
|
Vii V Healthcare: Attachment inhibitor
comparison in heavily treatment experienced patients.
ClinicalTrials.gov. Identifier: NCT02362503. First posted. February
13–2015.https://clinicaltrials.gov/ct2/show/NCT02362503
|
|
59
|
Xie D, Yao C, Wang L, Min W, Xu J, Xiao J,
Huang M, Chen B, Liu B, Li X, et al: An albumin-conjugated peptide
exhibits potent anti-HIV activity and long in vivo half-life.
Antimicrob Agents Chemother. 54:191–196. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang H, Jin R, Yao C, Zhang T, Wang M,
Xia W, Peng H, Wang X, Lu R, Wang C, et al: Combination of
long-acting HIV fusion inhibitor albuvirtide and LPV/r showed
potent efficacy in HIV-1 patients. AIDS Res Ther. 13:82016.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Xie D: International congress of drug
therapy in HIV infection 23–26 October 2016, Glasgow, UK. J Int
AIDS Soc. 19:214872016.PubMed/NCBI
|
|
62
|
Yang W, Xiao Q, Wang D, Yao C and Yang J:
Evaluation of pharmacokinetic interactions between long-acting
HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in
HIV-infected subjects, combined with clinical study and simulation
results. Xenobiotica. 47:133–143. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Song R, Franco D, Kao C-Y, Yu F, Huang Y
and Ho DD: Epitope mapping of ibalizumab, a humanized anti-CD4
monoclonal antibody with anti-HIV-1 activity in infected patients.
J Virol. 84:6935–6942. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bruno CJ and Jacobson JM: Ibalizumab: An
anti-CD4 monoclonal antibody for the treatment of HIV-1 infection.
J Antimicrob Chemother. 65:1839–1841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Merkenschlager M, Buck D, Beverley PC and
Sattentau QJ: Functional epitope analysis of the human CD4
molecule. The MHC class II-dependent activation of resting T cells
is inhibited by monoclonal antibodies to CD4 regardless whether or
not they recognize epitopes involved in the binding of MHC class II
or HIV gp120. J Immunol. 145:2839–2845. 1990.PubMed/NCBI
|
|
66
|
Delmonico FL, Knowles RW, Colvin RB,
Cavender DE, Kawai T, Bedle M, Stroka D, Preffer FI, Haug C and
Cosimi AB: Immunosuppression of cynomolgus renal allograft
recipients with humanized OKT4A monoclonal antibodies. Transplant
Proc. 25:784–785. 1993.PubMed/NCBI
|
|
67
|
Reimann KA, Burkly LC, Burrus B, Waite BC,
Lord CI and Letvin NL: In vivo administration to rhesus monkeys of
a CD4-specific monoclonal antibody capable of blocking AIDS virus
replication. AIDS Res Hum Retroviruses. 9:199–207. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Moore JP, Sattentau QJ, Klasse PJ and
Burkly LC: A monoclonal antibody to CD4 domain 2 blocks soluble
CD4-induced conformational changes in the envelope glycoproteins of
human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of
CD4+ cells. J Virol. 66:4784–4793. 1992.PubMed/NCBI
|
|
69
|
Jacobson JM, Kuritzkes DR, Godofsky E,
DeJesus E, Larson JA, Weinheimer SP and Lewis ST: Safety,
pharmacokinetics, and antiretroviral activity of multiple doses of
ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in
human immunodeficiency virus type 1-infected adults. Antimicrob
Agents Chemother. 53:450–457. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Kuritzkes DR, Jacobson J, Powderly WG,
Godofsky E, DeJesus E, Haas F, Reimann KA, Larson JL, Yarbough PO,
Curt V, et al: Antiretroviral activity of the anti-CD4 monoclonal
antibody TNX-355 in patients infected with HIV type 1. J Infect
Dis. 189:286–291. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
71
|
Fessel WJ, Anderson B, Follansbee SE,
Winters MA, Lewis ST, Weinheimer SP, Petropoulos CJ and Shafer RW:
The efficacy of an anti-CD4 monoclonal antibody for HIV-1
treatment. Antiviral Res. 92:484–487. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhang X-Q, Sorensen M, Fung M and Schooley
RT: Synergistic in vitro antiretroviral activity of a humanized
monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20).
Antimicrob Agents Chemother. 50:2231–2233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
United Biomedicals: Study to evaluate
safety and efficacy of UB421 antibody in HIV1 infected adults.
ClinicalTrials.gov. Identifier: NCT01668043. First posted. August
17–2012.https://clinicaltrials.gov/ct2/show/NCT01668043
|
|
74
|
Sáez-Cirión A, Bacchus C, Hocqueloux L,
Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P,
Melard A, Prazuck T, et al ANRS VISCONTI study group, :
Post-treatment HIV-1 controllers with a long-term virological
remission after the interruption of early initiated antiretroviral
therapy ANRS VISCONTI Study. PLoS Pathog. 9:e10032112013.
View Article : Google Scholar : PubMed/NCBI
|
